Qiagen N.V. is a biotechnology company that provides Sample to Insight solutions for molecular diagnostics, applied testing, academic research, and pharmaceutical research. Qiagen develops and markets sample preparation products, assay technologies, instruments, and bioinformatics software that help customers isolate, process, and analyze DNA, RNA, and proteins from biological materials. Its portfolio supports workflows in areas such as genotyping, gene expression, viral and bacterial analysis, next-generation sequencing, forensic testing, and clinical decision support. The company serves laboratories, healthcare organizations, research institutions, and life science companies worldwide, making it a key supplier in molecular testing and research workflows. Qiagen N.V. is headquartered in Venlo, the Netherlands, with major operational activities in Hilden, Germany.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$2.10B
▲ +5.7% YoY
Net Income (TTM)
$409M
▲ +408.3% YoY
Op. Margin
24.60%
▲ +14.8pp YoY
ROIC
8.53%
▲ +5.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$441M
▼ -11.0% YoY
Op. Cash Flow (TTM)
$654M
▼ -2.3% YoY
Net Debt
$713M
Cash & Equiv.
$1.10B
3Y CAGR: -0.8%
3Y CAGR: -7.5%
Continue Research
Peers
Diagnostics & Research · Pick stocks to compare with QGEN
Held by ETFs
QGEN is in 117 US ETFs. The largest of them, with QGEN's weight in each:
Vanguard Total International Stock ETFVXUS0.02%of the fund
iShares Core MSCI EAFE ETFIEFA0.04%of the fund
Qiagen (QGEN) in four numbers
Questions about Qiagen
Is Qiagen (QGEN) overvalued?
At $50.22, Qiagen's price is 77% above the $28.45 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 25.40 times earnings and 23.69 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Qiagen's fair value?
Intrinsiqq's calculator puts Qiagen's fair value at $28.45 a share. It grows earnings per share 0% a year for 5 years, applies an exit P/E of 22.4, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $21.34. Every input can be changed on the Intrinsic Value tab.
Is Qiagen a high-quality business?
Qiagen scores 36 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 8 checks computed from company filings. Its best check is share count change at -5.9%, and its weakest is margin trend at -2.3pp. The Quality tab shows every check against its target.
Does Qiagen (QGEN) pay a dividend, and how much?
Yes. Qiagen (QGEN) pays a dividend: $0.25 per share over the last twelve months, a dividend yield of 0.50% at the latest close. It has raised its dividend per share for 1 year in a row, shrinking at 49.2% a year over the last 2 years. The payout takes about 12.7% of earnings.
Source: company filings. Price: last close 30 Oct 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing QGEN
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.